Lung Cancer

Panelists discuss how patient selection for durvalumab consolidation requires careful consideration of autoimmune diseases, baseline lung function, and neurologic paraneoplastic syndromes, while emphasizing that most patients should receive immunotherapy unless they have severely active contraindications.

Panelists discuss how durvalumab consolidation after chemoradiation has become the standard of care for limited-stage SCLC based on the ADRIATIC trial, with most patients being considered candidates for the 2-year treatment course.

Greg Durm, MD, discusses factors that influence his decision to utilize perioperative treatment in patients with early-stage NSCLC.

Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

Optune Lua plus concurrent PD-1/PD-L1 inhibition has been approved in Japan for advanced non–small cell lung cancer after platinum-based chemotherapy.

In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

Ateganosine sequenced with cemiplimab was active in advanced NSCLC after disease progression on 2 or more standard therapies.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.

Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.

Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.